Drug Candidates for Allergic Diseases
Over the last two decades, novel drugs have emerged, paving the way for the personalized management of allergic diseases. Bronchoscopy studies and mouse models of asthma have provided initial insights into the mechanisms of allergic inflammation, establishing the role of Th2 type 2 cytokines, includ...
Sábháilte in:
| Formáid: | Online |
|---|---|
| Teanga: | Béarla |
| Foilsithe / Cruthaithe: |
MDPI - Multidisciplinary Digital Publishing Institute
2026
|
| Ábhair: | |
| Rochtain ar líne: | ONIX_20260416T142754_9783725860791_27 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
| _version_ | 1869517071445917696 |
|---|---|
| collection | Directory of Open Access Books |
| description | Over the last two decades, novel drugs have emerged, paving the way for the personalized management of allergic diseases. Bronchoscopy studies and mouse models of asthma have provided initial insights into the mechanisms of allergic inflammation, establishing the role of Th2 type 2 cytokines, including IL-4 and IL-5 IL-13, leading to the development of several monoclonal antibodies (mAbs) targeting these cytokines. Omalizumab was the first mAb used successfully to treat severe asthma patients. Subsequently, other drugs emerged, including antibodies that block IL-5 (mepolizumab, reslizumab) and the IL-5 receptor (benralizumab), the IL-4/IL-13 receptor alpha chain (dupilumab), and the thymic stromal lymphopoietin (Tezepelumab). These novel biologicals have been shown to be effective alternative therapies to corticosteroids, particularly in severe asthma management, where they have improved the quality of life of many patients. Given their success in asthma, these drugs have been used in other allergic diseases, including atopic dermatitis, chronic urticaria, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps (CRSwNP), and idiopathic hypereosinophilic syndrome. Currently, a number of novel antagonists targeting other inflammatory mediators are still in the preclinical stages of development. |
| format | Online |
| id | doab-20.500.12854ir-175122 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2026 |
| publishDateRange | 2026 |
| publishDateSort | 2026 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1751222026-04-16T19:03:01Z Drug Candidates for Allergic Diseases Teran, Luis Manuel Drugs Novel allergy therapies Asthma Atopic dermatitis Eosinophilic esophagitis Allergy immunotherapy thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries Over the last two decades, novel drugs have emerged, paving the way for the personalized management of allergic diseases. Bronchoscopy studies and mouse models of asthma have provided initial insights into the mechanisms of allergic inflammation, establishing the role of Th2 type 2 cytokines, including IL-4 and IL-5 IL-13, leading to the development of several monoclonal antibodies (mAbs) targeting these cytokines. Omalizumab was the first mAb used successfully to treat severe asthma patients. Subsequently, other drugs emerged, including antibodies that block IL-5 (mepolizumab, reslizumab) and the IL-5 receptor (benralizumab), the IL-4/IL-13 receptor alpha chain (dupilumab), and the thymic stromal lymphopoietin (Tezepelumab). These novel biologicals have been shown to be effective alternative therapies to corticosteroids, particularly in severe asthma management, where they have improved the quality of life of many patients. Given their success in asthma, these drugs have been used in other allergic diseases, including atopic dermatitis, chronic urticaria, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps (CRSwNP), and idiopathic hypereosinophilic syndrome. Currently, a number of novel antagonists targeting other inflammatory mediators are still in the preclinical stages of development. 2026-04-16T19:02:56Z 2026-04-16T19:02:56Z 2025 book ONIX_20260416T142754_9783725860791_27 9783725860791 9783725860807 https://directory.doabooks.org/handle/20.500.12854/175122 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/ https://mdpi.com/books/pdfview/book/12027 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-6080-7 10.3390/books978-3-7258-6080-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725860791 9783725860807 158 CH open access |
| spellingShingle | Drugs Novel allergy therapies Asthma Atopic dermatitis Eosinophilic esophagitis Allergy immunotherapy thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries Drug Candidates for Allergic Diseases |
| title | Drug Candidates for Allergic Diseases |
| title_full | Drug Candidates for Allergic Diseases |
| title_fullStr | Drug Candidates for Allergic Diseases |
| title_full_unstemmed | Drug Candidates for Allergic Diseases |
| title_short | Drug Candidates for Allergic Diseases |
| title_sort | drug candidates for allergic diseases |
| topic | Drugs Novel allergy therapies Asthma Atopic dermatitis Eosinophilic esophagitis Allergy immunotherapy thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries |
| topic_facet | Drugs Novel allergy therapies Asthma Atopic dermatitis Eosinophilic esophagitis Allergy immunotherapy thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries |
| url | ONIX_20260416T142754_9783725860791_27 |